Join
Live feed
·
PRReleasevia Quantisnow
Edgewise Therapeutics Inc. logo

Edgewise Therapeutics Doses First Patient in Phase 2 EQUINOX-HFpEF Trial of EDG-15400

ByQuantisnow·Wall Street's wire, on your screen.
EWTX· Edgewise Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track EWTX (Edgewise Therapeutics Inc.) and more on Quantisnow.